## Highlights of This Issue 2503

### SPECIAL FEATURES

**2505**  
Minimal Residual Disease in Breast Cancer: In Blood Veritas  
Giulia Siravegna and Alberto Bardelli  
*See related article, p. 2643*

**2508**  
Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer  
Alastair M. Thompson

**2516**  
Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer  
Gary L. Johnson, Timothy J. Stuhlmiller, Steven P. Angus, Jon S. Zawistowski, and Lee M. Graves

### CCR Focus

**2524**  
The Language of Pharmacodynamics  
Susan E. Bates

**2525**  
Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine  
William Douglas Figg and David R. Newell

**2530**  
Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology  
Daniel L. Hertz and Howard L. McLeod

**2541**  
Genome-Wide Association Study: A Useful Tool to Identify Common Genetic Variants Associated with Drug Toxicity and Efficacy in Cancer Pharmacogenomics  
Siew-Kee Low, Atsushi Takahashi, Taisei Mushiroda, and Michiaki Kubo

**2553**  
Circulating Tumor Cells: A Multifunctional Biomarker  
Timothy A. Yap, David Lorente, Aurelius Omlin, David Olmos, and Johann S. de Bono

**2569**  
*In Vivo* Imaging as a Pharmacodynamic Marker  
Astrid A.M. van der Veldt and Adriaan A. Lammertsma

**2578**  
Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations  
Robert Kinders, Kate Ferry-Galow, Lihua Wang, Apurva K. Srivastava, Jiuping (Jay) Ji, and Ralph E. Parchment

**2587**  
Pharmacodynamic Biomarkers: Falling Short of the Mark?  
Justin F. Gainor, Dan L. Longo, and Bruce A. Chabner

## HUMAN CANCER BIOLOGY

**2595**  
FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression  
Jiujie Cui, Min Shi, Dacheng Xie, Daoyan Wei, Zhiliang Jia, Shaojiang Zheng, Yong Gao, Suyun Huang, and Keping Xie

**2607**  
Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration  
Edmund K. Bartlett, Patricia A. Fetsch, Armando C. Filie, Andrea Abati, Seth M. Steinberg, John R. Wunderlich, Donald E. White, Daniel J. Stephens, Francesco M. Marincola, Steven A. Rosenberg, and Udai S. Kammula

**2617**  
mir-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression  
Xuanwu Chen, Xuegang Wang, Anming Ruan, Weiwei Han, Yan Zhao, Xing Lu, Pei Xiao, Hangchuan Shi, Rong Wang, Li Chen, Shaoyong Chen, Quansheng Du, Hongmei Yang, and Xiaoping Zhang

**2631**  
Regulation of Colorectal Carcinoma Stemness, Growth, and Metastasis by an miR-200c-Sox2-Negative Feedback Loop Mechanism  
Yan-Xia Lu, Li Yuan, Xiao-Lei Xue, Min Zhou, Yan Liu, Chao Zhang, Jing-Ping Li, Lin Zheng, Min Hong, and Xue-Nong Li
Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer
See related article, p. 2505

CANCER THERAPY: PRECLINICAL

Id1-Induced IGF-II and Its Autocrine/Endocrine Promotion of Esophageal Cancer Progression and Chemoresistance—Implications for IGF-II and IGF-IR–Targeted Therapy
Bin Li, Sai Wah Tsao, Kwok Wah Chan, Dale L. Ludwig, Ruslan Novosyadlyy, Yuk Yin Li, Qing Yu He, and Annie L.M. Cheung

COX-2–Independent Effects of Celecoxib Sensitize Lymphoma B Cells to TRAIL-Mediated Apoptosis
Anne-Sophie Gallouet, Marion Traversal, Laurence Bresson-Bepoldin, Fabien Guilloton, Céline Pangault, Sylvie Caulet-Maugendre, Thierry Lamy, Karin Tarte, and Thierry Guillaudeux

Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo
Yansheng Hao, Bjorn Chapuy, Stefano Monti, Heather H. Sun, Scott J. Rodig, and Margaret A. Shipp

Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
Smita K. Nair, Gabriel De Leon, David Boczkowski, Robert Schmittling, Weihua Xie, Janet Staats, Rebecca Liu, Laura A. Johnson, Kent Weinhold, Gary E. Archer, John H. Sampson, and Duane A. Mitchell

IMAGING, DIAGNOSIS, PROGNOSIS

Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume
Andrea G. Rockall, Norbert Avril, Raymond Lam, Robert Iannone, P. David Mozley, Christine Parkinson, Donald Bergstrom, Evis Sala, Shah-Jalal Sarker, Lain A. McNeish, and James D. Brenton
Table of Contents

2761 A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
Rita A. Busuttil, Joshy George, Richard W. Tothill, Kylie Ioculano, Adam Kowalczyk, Catherine Mitchell, Stephen Lade, Patrick Tan, Izhak Haviv, and Alex Boussioutas

2773 In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai, and David L. Rimm

CANCER THERAPY: CLINICAL

2783 Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing

2793 A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases
Josep Tabernero, Maria Elena Elez, Maria Herranz, Isabel Rico, Ludmila Prudkin, Jordi Andreu, Jose Mateos, Maria Josep Carreras, May Han, James Gifford, Marc Credi, Wei Yin, Shefali Agarwal, Philip Komarnitsky, and Jose Baselga

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

2805 Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff
Renata Duchnowska, Jeff Sperinde, Ahmed Chenna, Mojgan Haddad, Agnes Paquet, Yolanda Lie, Jodi M. Weidler, Weidong Huang, John Winslow, Tomasz Jankowski, Bogumila Czartoryska-Arlikowicz, Piotr J. Wysocki, Malgorzata Foszczyńska-Kłoda, Barbara Radecka, Maria M. Litwinuik, Jolanta Żok, Michal Wiśniewski, Dorota Zuziak, Wojciech Biernat, and Jacek Jassem

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a brain section from a mouse injected with a brain seeking variant of the human breast cancer cell line MDA-MB-231. Immunohistochemical staining indicates a lack of MGMT expression in the tumor cells. Tissue was stained with anti-MGMT antibody and counterstained with hematoxylin and eosin. For details, see the article by Palmieri and colleagues on page 2727 of this issue.
Clinical Cancer Research

20 (10)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/10

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.